BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stokol T, Serpa PBS, Zahid MN, Brooks MB. Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation. Front Vet Sci 2016;3:99. [PMID: 27909693 DOI: 10.3389/fvets.2016.00099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Stokol T, Serpa PBS, Brooks MB, Divers T, Ness S. Subcutaneous Administration of Low-Molecular-Weight Heparin to Horses Inhibits Ex Vivo Equine Herpesvirus Type 1-Induced Platelet Activation. Front Vet Sci 2018;5:106. [PMID: 29892605 DOI: 10.3389/fvets.2018.00106] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Bedenice D, Johnson AL. Neurologic Conditions Affecting the Equine Athlete. Vet Clin North Am Equine Pract 2018;34:277-97. [PMID: 30007448 DOI: 10.1016/j.cveq.2018.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Motta NAV, Autran LJ, Brazão SC, Lopes RO, Scaramello CBV, Lima GF, Brito FCF. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. Int Immunopharmacol 2021;92:107336. [PMID: 33418248 DOI: 10.1016/j.intimp.2020.107336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Theuerkauf K, Obach-Schröck C, Staszyk C, Moritz A, Roscher KA. Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome. J Vet Diagn Invest 2022;:10406387221077969. [PMID: 35168432 DOI: 10.1177/10406387221077969] [Reference Citation Analysis]
5 Dunkel B. Hypercoagulation and thrombosis associated with infection in horses. Equine Vet Educ. [DOI: 10.1111/eve.13598] [Reference Citation Analysis]